ODM-204 is a novel nonsteroidal compound that has a dual mechanism of action against CYP17A1 and AR. In vitro, ODM-204 inhibited proliferation of VCaP and LNCaP cells. In vivo, oral administration of this compound significantly reduced VCaP xenograft tumour growth in mice. Oral ODM-204 showed potent inhibition of steroid biosynthesis in rats and monkeys. These data formed the basis of the DUALIDES first-in-man study of ODM-204 in castration-resistant prostate cancer (CRPC).
References
Original article
Oksala, R. et al. Discovery and development of ODM-204: a novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1. J. Steroid Biochem. Mol. Biol. https://doi.org/10.1016/j.jsbmb.2018.02.004 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stone, L. New nonsteroidal compound for treating CRPC. Nat Rev Urol 15, 656 (2018). https://doi.org/10.1038/s41585-018-0072-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0072-3
